|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.98 USD | +0.35% |
|
-.--% | - |
| 19/05 | Endologix LLC acquired Pounce? Thrombectomy System from Surmodics, Inc. | CI |
| 10/12 | Surmodics, Inc. acquired certain assets from Biocoat, Incorporated. | CI |
Company Valuation: SurModics
Data adjusted to current consolidation scope
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 617.1 | 531.1 | 771.3 | 425.8 | 453.6 | 553.3 |
| Change | - | -13.93% | 45.22% | -44.8% | 6.53% | 21.98% |
| Enterprise Value (EV) 1 | 561.8 | 473.8 | 746.1 | 421.6 | 441.5 | 546.4 |
| Change | - | -15.66% | 57.47% | -43.5% | 4.72% | 23.77% |
| P/E Ratio | 83.2x | 486x | 185x | -15.5x | -292x | -47.3x |
| PBR | 5.04x | 4.06x | 5.52x | 3.93x | 3.79x | 4.67x |
| PEG | - | -5.7x | 1x | 0x | 3.1x | -0x |
| Capitalization / Revenue | 6.17x | 5.6x | 7.34x | 4.26x | 3.42x | 4.39x |
| EV / Revenue | 5.61x | 4.99x | 7.1x | 4.22x | 3.33x | 4.33x |
| EV / EBITDA | 39.6x | 78.8x | 61.3x | -32.6x | 31.3x | 81x |
| EV / EBIT | 81.9x | -379x | 180x | -19.1x | 78.8x | -281x |
| EV / FCF | -39.1x | 67.3x | 150x | -62.6x | 31.3x | 79.6x |
| FCF Yield | -2.56% | 1.49% | 0.67% | -1.6% | 3.2% | 1.26% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.55 | 0.08 | 0.3 | -1.96 | -0.11 | -0.82 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 100.1 | 94.86 | 105.1 | 99.95 | 132.6 | 126.1 |
| EBITDA 1 | 14.17 | 6.012 | 12.17 | -12.94 | 14.12 | 6.749 |
| EBIT 1 | 6.857 | -1.251 | 4.155 | -22.08 | 5.603 | -1.945 |
| Net income 1 | 7.592 | 1.123 | 4.237 | -27.27 | -1.536 | -11.54 |
| Net Debt 1 | -55.29 | -57.32 | -25.16 | -4.192 | -12.1 | -6.87 |
| Reference price 2 | 45.74 | 38.91 | 55.60 | 30.40 | 32.09 | 38.78 |
| Nbr of stocks (in thousands) | 13,491 | 13,650 | 13,872 | 14,005 | 14,134 | 14,267 |
| Announcement Date | 03/12/19 | 02/12/20 | 24/11/21 | 23/11/22 | 22/11/23 | 20/11/24 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 61Cr | |
| 22.43x | 3.32x | 12.49x | 2.85% | 16TCr | |
| 20.17x | 3.48x | 12.52x | 3.56% | 10TCr | |
| 14.82x | 0.18x | 11.11x | 0.84% | 5.47TCr | |
| 35.03x | 8.65x | 23.28x | 1.1% | 5.37TCr | |
| 36.82x | 2.95x | 10.13x | 2.61% | 4.07TCr | |
| 34.98x | 1.3x | 11.43x | 0.22% | 3.09TCr | |
| 30.55x | 5.45x | 17.4x | -.--% | 2.89TCr | |
| 39.3x | 6.8x | 24.52x | 0.27% | 2.34TCr | |
| 24.9x | 3.17x | 12.94x | 1.3% | 2.12TCr | |
| Average | 28.78x | 3.92x | 15.09x | 1.42% | 5.12TCr | |
| Weighted average by Cap. | 25.71x | 3.70x | 14.07x | 2.07% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SRDX Stock
- Valuation SurModics
Select your edition
All financial news and data tailored to specific country editions
